LYEL

Lyell Immunopharma, Inc.

Price Chart

Latest Quote

$13.00

+0.37 (+2.93%)

Current Price

Previous Close	$12.63
Open	$12.65
Day High	$13.25
Day Low	$12.35
Volume	132,420

Fetched: 2026-06-25T08:25:45

Stock Information

Shares Outstanding	23.33M
Total Debt	$48.85M
Cash Equivalents	$254.02M
Revenue	$31K
Net Income	$-246.41M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$303.34M
EPS (TTM)	$-13.62
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$97.94M
Sales	$31K
Income	$-246.41M
Book/sh	$11.73
Cash/sh	$10.89
Employees	161

Financial Ratios

Quick Ratio	6.88
Current Ratio	7.24
Debt/Eq	17.85

Returns & Margins

ROA	-29.87%
ROE	-80.76%
Gross Margin	100.00%
Operating Margin	-2213050.00%

Ownership

Insider Ownership	39.84%
Institutional Ownership	58.33%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-15.48
P/S	9785.26
P/B	1.11

Analyst Data

Recommendation	buy
Target Price	$37.17

Technical Indicators

SMA20	$13.74
SMA50	$17.84
SMA200	$20.78
RSI	53.17
ATR	1.0568

Shares Float	6.49M
Short Float	6.83%
Short Ratio	19.69
Volatility	-0.09
Rel Volume	0.91

Performance History

Week	+4.50%
Month	-25.54%
Quarter	-34.01%
6 Months	-61.00%
YTD	-55.14%
Year	+44.61%
3 Years	-79.62%
10 Years	-96.15%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$13.00	132,900
2026-06-23	$12.63	152,500
2026-06-22	$11.97	184,600
2026-06-18	$12.74	360,100
2026-06-17	$12.52	167,100
2026-06-16	$12.44	198,600
2026-06-15	$13.55	82,700
2026-06-12	$13.50	99,900
2026-06-11	$13.72	142,500
2026-06-10	$13.22	146,400
2026-06-09	$12.70	99,200
2026-06-08	$12.31	124,800
2026-06-05	$11.97	96,700
2026-06-04	$13.05	127,400
2026-06-03	$12.57	413,000
2026-06-02	$14.89	117,900
2026-06-01	$17.15	82,600
2026-05-29	$17.33	65,600
2026-05-28	$16.83	57,200
2026-05-27	$16.73	84,000
2026-05-26	$16.37	134,000

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

📰 Latest News

Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?

Simply Wall St. • 2026-06-09T10:49:59Z

Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study

MT Newswires • 2026-06-08T10:46:44Z

Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks • 2026-06-04T13:35:03Z

Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances

MarketBeat • 2026-05-27T08:03:20Z

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)

Zacks • 2026-05-19T13:35:02Z

Lyell Immunopharma: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-12T22:10:19Z

Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs

BioPharma Dive • 2026-02-13T11:00:00Z

The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar

Zacks • 2025-12-26T07:33:00Z

4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow

Zacks • 2025-12-24T15:51:00Z

Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain

Simply Wall St. • 2025-12-17T15:37:40Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$36,000	$61,000	$130,000	$84,683,000
Operating Revenue	$36,000	$61,000	$130,000	$84,683,000
Expenses
Total Expenses	$201,665,000	$220,335,000	$247,138,000	$271,741,000
Other Income Expense	$-85,899,000	$-146,788,000	$-11,077,000	$-3,113,000
Other Non Operating Income Expenses	$-18,124,000	$4,694,000	$1,846,000	$1,887,000
Net Non Operating Interest Income Expense	$13,080,000	$24,068,000	$23,453,000	$7,053,000
Operating Expense	$201,665,000	$220,335,000	$247,138,000	$271,741,000
Other Operating Expenses	$-2,145,000	$-3,309,000	$-2,790,000	$-4,754,000
General And Administrative Expense	$45,135,000	$52,041,000	$66,983,000	$117,307,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Net Interest Income	$13,080,000	$24,068,000	$23,453,000	$7,053,000
Interest Income	$13,080,000	$24,068,000	$23,453,000	$7,053,000
Normalized Income	$-206,673,000	$-191,512,000	$-221,709,000	$-178,118,000
Net Income From Continuing And Discontinued Operation	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Total Operating Income As Reported	$-269,404,000	$-358,755,000	$-247,008,000	$-187,058,000
Net Income Common Stockholders	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Net Income	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Net Income Including Noncontrolling Interests	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Net Income Continuous Operations	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Pretax Income	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Special Income Charges	$-67,775,000	$-151,482,000	$-12,923,000	$-5,000,000
Interest Income Non Operating	$13,080,000	$24,068,000	$23,453,000	$7,053,000
Operating Income	$-201,629,000	$-220,274,000	$-247,008,000	$-187,058,000
Per Share
Diluted EPS	$-12.91	$-23.26	$-18.70	$-14.80
Basic EPS	$-12.91	$-23.26	$-18.70	$-14.80
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-122,315,000	$-49,161,000	$-213,835,000	$-164,038,000
Total Unusual Items	$-67,775,000	$-151,482,000	$-12,923,000	$-5,000,000
Total Unusual Items Excluding Goodwill	$-67,775,000	$-151,482,000	$-12,923,000	$-5,000,000
Reconciled Depreciation	$11,539,000	$19,631,000	$20,250,000	$18,020,000
EBITDA (Bullshit earnings)	$-190,090,000	$-200,643,000	$-226,758,000	$-169,038,000
EBIT	$-201,629,000	$-220,274,000	$-247,008,000	$-187,058,000
Diluted Average Shares	$21,251,353	$14,743,777	$12,549,000	$12,354,000
Basic Average Shares	$21,251,353	$14,743,777	$12,549,000	$12,354,000
Diluted NI Availto Com Stockholders	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Other Special Charges	$66,332,000	$87,184,000	-	-
Write Off	$0	$13,001,000	$12,923,000	$5,000,000
Impairment Of Capital Assets	$1,443,000	$51,297,000	$0	$0
Research And Development	$158,675,000	$171,603,000	$182,945,000	$159,188,000
Selling General And Administration	$45,135,000	$52,041,000	$66,983,000	$117,307,000
Other Gand A	$45,135,000	$52,041,000	$66,983,000	$117,307,000
Restructuring And Mergern Acquisition	-	$87,184,000	$0	$0

Fetched: 2026-06-23

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Total Assets	$340,052,000	$490,859,000	$750,029,000	$937,561,000
Total Non Current Assets	$79,113,000	$111,265,000	$195,343,000	$286,266,000
Other Non Current Assets	$6,471,000	$6,312,000	$4,519,000	$4,960,000
Investmentin Financial Assets	$0	$13,014,000	$16,506,000	$70,117,000
Current Assets	$260,939,000	$379,594,000	$554,686,000	$651,295,000
Other Current Assets	$13,719,000	$9,067,000	$8,463,000	$11,143,000
Cash Cash Equivalents And Short Term Investments	$247,220,000	$370,527,000	$546,223,000	$640,152,000
Cash And Cash Equivalents	$60,181,000	$105,597,000	$145,647,000	$123,554,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$50,994,000	$58,968,000	$63,167,000	$67,702,000
Long Term Debt And Capital Lease Obligation	$41,921,000	$50,994,000	$56,894,000	$63,168,000
Current Debt And Capital Lease Obligation	$9,073,000	$7,974,000	$6,273,000	$4,534,000
Liabilities
Total Liabilities Net Minority Interest	$91,850,000	$108,035,000	$95,077,000	$104,309,000
Total Non Current Liabilities Net Minority Interest	$42,438,000	$54,247,000	$60,558,000	$67,281,000
Other Non Current Liabilities	$517,000	$3,253,000	$3,664,000	$4,113,000
Current Liabilities	$49,412,000	$53,788,000	$34,519,000	$37,028,000
Other Current Liabilities	$2,559,000	$2,999,000	$3,069,000	$6,708,000
Current Deferred Liabilities	$2,535,000	$483,000	-	$0
Payables And Accrued Expenses	$24,091,000	$23,097,000	$10,543,000	$10,339,000
Payables	$2,893,000	$12,966,000	$4,817,000	$3,917,000
Accounts Payable	$2,893,000	$5,366,000	$4,817,000	$3,917,000
Other Payable	-	$7,600,000	-	-
Non Current Deferred Liabilities	-	-	-	$0
Equity
Common Stock Equity	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Total Equity Gross Minority Interest	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Stockholders Equity	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Gains Losses Not Affecting Retained Earnings	$242,000	$291,000	$-94,000	$-7,599,000
Other Equity Adjustments	$242,000	$291,000	$-94,000	$-7,599,000
Retained Earnings	$-1,619,554,000	$-1,345,106,000	$-1,002,112,000	$-767,480,000
Other
Ordinary Shares Number	$21,251,353	$14,743,777	$12,697,885	$12,478,350
Share Issued	$21,251,353	$14,743,777	$12,697,885	$12,478,350
Tangible Book Value	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Invested Capital	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Working Capital	$211,527,000	$325,806,000	$520,167,000	$614,267,000
Capital Lease Obligations	$50,994,000	$58,968,000	$63,167,000	$67,702,000
Total Capitalization	$248,202,000	$382,824,000	$654,952,000	$833,252,000
Additional Paid In Capital	$1,867,512,000	$1,727,638,000	$1,657,133,000	$1,608,306,000
Capital Stock	$2,000	$1,000	$25,000	$25,000
Common Stock	$2,000	$1,000	$25,000	$25,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$41,921,000	$50,994,000	$56,894,000	$63,168,000
Current Deferred Revenue	$2,535,000	$483,000	-	$0
Current Capital Lease Obligation	$9,073,000	$7,974,000	$6,273,000	$4,534,000
Pensionand Other Post Retirement Benefit Plans Current	$11,154,000	$19,235,000	$14,634,000	$15,447,000
Current Accrued Expenses	$21,198,000	$10,131,000	$5,726,000	$6,422,000
Investments And Advances	$19,000,000	$32,014,000	$48,507,000	$115,041,000
Other Investments	$19,000,000	$19,000,000	$32,001,000	$44,924,000
Net PPE	$53,642,000	$72,939,000	$142,317,000	$166,265,000
Accumulated Depreciation	$-74,278,000	$-70,679,000	$-51,647,000	$-32,384,000
Gross PPE	$127,920,000	$143,618,000	$193,964,000	$198,649,000
Leases	$79,739,000	$79,613,000	$118,319,000	$116,930,000
Construction In Progress	$452,000	$241,000	$128,000	$4,148,000
Other Properties	$45,243,000	$60,845,000	$73,031,000	$75,224,000
Machinery Furniture Equipment	$2,486,000	$2,919,000	$2,486,000	$2,347,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$187,039,000	$264,930,000	$400,576,000	$516,598,000
Available For Sale Securities	-	$13,014,000	$16,506,000	$70,117,000
Treasury Shares Number	-	-	$0	-
Non Current Deferred Revenue	-	-	-	$0

Fetched: 2026-06-23

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-150,804,000	$-162,858,000	$-166,380,000	$-193,831,000
Operating Activities
Operating Cash Flow	$-150,024,000	$-162,394,000	$-163,694,000	$-169,555,000
Cash Flow From Continuing Operating Activities	$-150,024,000	$-162,394,000	$-163,694,000	$-169,555,000
Operating Gains Losses	$22,559,000	$1,311,000	$1,509,000	$-1,753,000
Investing Activities
Capital Expenditure	$-780,000	$-464,000	$-2,686,000	$-24,276,000
Investing Cash Flow	$54,097,000	$122,424,000	$184,048,000	$-11,540,000
Cash Flow From Continuing Investing Activities	$54,097,000	$122,424,000	$184,048,000	$-11,540,000
Net Other Investing Changes	$-41,195,000	$-31,346,000	-	-
Financing Activities
Issuance Of Capital Stock	$50,000,000	$0	$0	$0
Financing Cash Flow	$50,406,000	$1,326,000	$1,743,000	$10,635,000
Cash Flow From Continuing Financing Activities	$50,406,000	$1,326,000	$1,743,000	$10,635,000
Net Other Financing Charges	$-1,000	$-76,000	$-457,000	$-461,000
Net Common Stock Issuance	$50,000,000	$0	$0	$0
Common Stock Issuance	$50,000,000	$0	$0	$0
Repurchase Of Capital Stock	-	-	-	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$61,766,000	$107,287,000	$145,931,000	$123,834,000
Beginning Cash Position	$107,287,000	$145,931,000	$123,834,000	$294,294,000
Changes In Cash	$-45,521,000	$-38,644,000	$22,097,000	$-170,460,000
Proceeds From Stock Option Exercised	$407,000	$1,402,000	$2,200,000	$11,096,000
Net Investment Purchase And Sale	$95,785,000	$154,234,000	$186,734,000	$12,736,000
Sale Of Investment	$374,684,000	$548,941,000	$663,614,000	$419,052,000
Purchase Of Investment	$-278,899,000	$-394,707,000	$-476,880,000	$-406,316,000
Net PPE Purchase And Sale	$-493,000	$-464,000	$-2,686,000	$-24,276,000
Sale Of PPE	$287,000	$0	$0	-
Purchase Of PPE	$-780,000	$-464,000	$-2,686,000	$-24,276,000
Change In Working Capital	$-9,894,000	$-3,120,000	$3,421,000	$-82,015,000
Change In Other Current Liabilities	$-2,736,000	$-411,000	$-449,000	$4,402,000
Change In Payables And Accrued Expense	$-9,981,000	$-4,484,000	$745,000	$204,000
Change In Accrued Expense	$-7,642,000	$-1,250,000	$-719,000	$-463,000
Change In Payable	$-2,339,000	$-3,234,000	$1,464,000	$667,000
Change In Account Payable	$-2,339,000	$-3,234,000	$1,464,000	$667,000
Change In Prepaid Assets	$2,823,000	$1,775,000	$3,125,000	$-1,968,000
Other Non Cash Items	$61,907,000	$80,017,000	$-4,653,000	$-6,683,000
Stock Based Compensation	$41,829,000	$33,144,000	$47,084,000	$81,924,000
Asset Impairment Charge	$1,443,000	$64,298,000	$12,923,000	$5,000,000
Amortization Of Securities	$-4,959,000	$-14,681,000	$-9,596,000	$-930,000
Depreciation Amortization Depletion	$11,539,000	$19,631,000	$20,250,000	$18,020,000
Depreciation And Amortization	$11,539,000	$19,631,000	$20,250,000	$18,020,000
Gain Loss On Investment Securities	$19,215,000	$-30,000	-	$-1,856,000
Gain Loss On Sale Of PPE	$3,344,000	$1,341,000	$1,509,000	$103,000
Net Income From Continuing Operations	$-274,448,000	$-342,994,000	$-234,632,000	$-183,118,000
Preferred Stock Payments	-	-	-	$0
Common Stock Payments	-	-	-	$0
Change In Other Working Capital	-	-	-	$-84,653,000
Net Investment Properties Purchase And Sale	-	-	-	-
Purchase Of Investment Properties	-	-	-	-

Fetched: 2026-06-23